<Blinded Review: TIME_ANON_0654>
**Composite Score:** 3.6 / 10.0 (Rigor: 1.0/3.5 | Claims: 1.0/2.5 | Biology: 0.7/2.0 | Reproducibility: 0.9/2.0)
**Bias Category:** Statistical/Design
**Verdict:** Reject (Fundamental Flaws)
**Study Modality:** Hybrid Computational + Wet-Lab
**Technology Maturity:** Commodity/Hype-Cycle Template
**Epistemic Stage:** Clinical/Observational

OVERALL_SCORE: 3.6/10
VERDICT: FAILED
ESTIMATED_DECADE: 2020s

---

### 1. Executive Summary / SUMMARY
This single-center retrospective clinical association study investigates the relationship between methylenetetrahydrofolate reductase (*MTHFR*) `677C>T` and `1298A>C` polymorphisms and "H-type hypertension" (essential hypertension with plasma homocysteine $\ge 10\ \mu\text{mol/L}$) among 215 hospitalized patients with ischemic stroke and hypertension at Taian City Central Hospital, China (`n = 192` H-type hypertension vs. `n = 23` non-H-type hypertension). Using a commercial fluorescence detector (`TL998A`) for genotyping, `SHEsis` for two-SNP linkage disequilibrium and haplotype analysis, and `SPSS 25.0` for univariate and multivariate logistic regression, the authors report that the *MTHFR* `677C>T` `TT` genotype ($\text{OR} = 2.615, P = 0.021$) and `T-A` haplotype ($\text{OR} = 2.029, P = 0.022$) are risk factors for H-type hypertension while the `C-A` haplotype ($\text{OR} = 0.485, P = 0.028$) is protective. Because *MTHFR* is the canonical enzyme converting 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate for homocysteine remethylation, testing whether *MTHFR* `677C>T` associates with homocysteine $\ge 10\ \mu\text{mol/L}$ is biologically trivial (merely re-confirming that a known hypomorphic homocysteine-raising variant raises homocysteine). More critically, a forensic statistical and table audit uncovers **severe methodological and numerical errors**: (1) fitting a 15-predictor multivariate logistic regression model to a dataset with only $n=23$ controls ($\text{EPV} = 1.53$), causing extreme parameter instability (`HDL-C` 95% CI: `0.003–639.855`); (2) misinterpreting an ordinal additive regression slope (`CC=0, CT=1, TT=2`) as the odds ratio for the `TT` genotype; (3) swapping the laboratory values of Total Cholesterol (`TC`) and Triglycerides (`TG`) in `Table 1`; and (4) reporting an incorrect percentage in `Table 4` (`27/192` reported as `21.7%` instead of `14.1%`, causing the table percentages to sum to `107.6%`).

### 2. Methodological & Statistical Audit / STRENGTHS, WEAKNESSES & METHODOLOGICAL AUDIT

#### Key Strengths
- **Standardized clinical recruitment and HWE verification:** All 215 hospitalized ischemic stroke + hypertension patients underwent fasting venous blood sampling within 24 h of admission, and genotype distributions at both `677C>T` and `1298A>C` conformed to Hardy-Weinberg equilibrium in both groups (`P = 0.48–0.74`).

#### Methodological Weaknesses & Audit Findings
1. **Severe Logistic Regression Overfitting ($n=23$ Non-Events vs. 15 Covariates; $\text{EPV} = 1.53$) in `Table 3`:**
   - In a binary logistic regression model, the effective sample size is governed by the smaller outcome category—here, only **$n = 23$ patients** in the non-H-type hypertension group (vs. $n = 192$ in the H-type group).
   - Despite having only 23 observations in the reference outcome class (and despite none of the metabolic variables having $P < 0.20$ in univariate `Table 1`), the authors simultaneously entered **15 independent variables** (`Gender`, `Age`, `MTHFR 677C>T`, `MTHFR 1298A>C`, `Diabetes`, `Smoking`, `Drinking`, `TC`, `TG`, `LDL-C`, `FBG`, `UA`, `ApoA1`, `ApoB`, `HDL-C`) into a single multivariate logistic regression (`Table 3`).
   - This yields an Events-Per-Variable (`EPV`) ratio of $23 / 15 = 1.53$ (violating the standard statistical minimum of $\text{EPV} \ge 10$) and simultaneously enters collinear lipid fractions (`TC`, `LDL-C`, `HDL-C`, `TG`, `ApoA1`, `ApoB`). The resulting numerical instability is glaringly evident in `Table 3`:
     - `TC`: $\beta = 1.985, \text{OR} = 7.277, 95\%\text{ CI } [0.270\text{–}195.915]$
     - `HDL-C`: $\beta = 0.397, \text{OR} = 1.487, 95\%\text{ CI } [0.003\text{–}639.855]$
     - `apoB`: $\beta = -3.839, \text{OR} = 0.022, 95\%\text{ CI } [0.000\text{–}51.280]$
     - `apoA1`: $\beta = -4.960, \text{OR} = 0.007, 95\%\text{ CI } [0.000\text{–}3.357]$
2. **Misrepresentation of Ordinal Per-Allele Coding (`0, 1, 2`) as the `"TT Genotype"` Odds Ratio:**
   - In `Results` line 115, the authors state that `MTHFR (677C>T)` was entered into the logistic regression as a single ordinal variable coded `(CC = 0, CT = 1, TT = 2)`. Accordingly, `Table 3` line 124 has only a single row for `MTHFR (677C>T)` reporting $\beta = 0.961, \text{SE} = 0.417, \text{Wald} = 5.302, P = 0.021, \text{OR} = \exp(0.961) = 2.615\ [1.154\text{–}5.926]$.
   - Under `(0, 1, 2)` coding, $\exp(\beta) = 2.615$ is the **per-T-allele multiplicative odds ratio** ($\text{CT vs. CC} = 2.615$, and $\text{TT vs. CC} = 2.615^2 = 6.84$), **not** the odds ratio of the `TT` genotype! Yet the Abstract (line 11), Results (line 115), Discussion (lines 202, 206), and Conclusion (line 215) all falsely report $\text{OR} = 2.615$ as the odds ratio of the **`TT` genotype**.
3. **Swapped Laboratory Values (`TC` and `TG`), Wrong Units (`UA`), and Inconsistent Summary Metrics in `Table 1`:**
   - In `Table 1` (lines 83–86), the authors report:
     - `TG (mmol/L)`: `4.46 ± 1.04` (H-type) vs. `4.41 ± 1.14` (Non-H-type)
     - `TC (mmol/L)`: `1.23 (0.89, 1.75)` (H-type) vs. `1.56 ± 0.64` (Non-H-type)
     - `LDL-C (mmol/L)`: `2.83 ± 0.84` vs. `2.83 ± 0.94`
     - `HDL-C (mmol/L)`: `1.21 ± 0.28` vs. `1.18 ± 0.33`
   - Biochemically and arithmetically, Total Cholesterol (`TC`) is the sum of `LDL-C + HDL-C + VLDL-C` ($\approx 2.83 + 1.21 + 0.42 = 4.46\text{ mmol/L}$); it is physically impossible for `TC` to be `1.23 mmol/L` when `LDL-C` alone is `2.83 mmol/L`! The authors transposed the row labels for Triglycerides (`TG`, median `1.23 mmol/L`) and Total Cholesterol (`TC`, mean `4.46 mmol/L`) in `Table 1`.
   - Furthermore, in `Table 1` rows `TC` (line 84) and `UA` (line 88), the H-type column reports Median `(P25, P75)` (`1.23 (0.89, 1.75)` and `285 (236, 336)`) while the Non-H-type column in the *exact same row* reports Mean $\pm$ SD (`1.56 ± 0.64` and `267 ± 79.5`), and uric acid (`UA`, `285` vs `267`) is mislabeled with units of `mmol/L` instead of $\mu\text{mol/L}$ (a 1,000-fold unit error).
4. **Arithmetic Error in `Table 4` and Main Text (Lines 143, 151):**
   - In `Table 4` (`H-type hypertension group`, $N=192$), the cell for `CT/AC` (line 151) is reported as `27 (21.7%)` (and repeated in text line 143). However, $27 / 192 = 14.06\%$ (`14.1%`, as correctly listed in `Table 7` line 194), whereas `21.7%` was copied from the `Non-H-type` group in `Table 5` ($5 / 23 = 21.7\%$). Because of this error, the genotype percentages in `Table 4` sum to $5.2\% + 4.7\% + 3.1\% + 25.5\% + 21.7\% + 46.4\% + 1.0\% = 107.6\%$.
5. **Additional Factual and Copy-Editing Errors:**
   - Line 20 states: *"MTHFR, located on chromosome 1p63.6"* — human chromosome 1p terminates at `1p36.33` (`1p63.6` does not exist; *MTHFR* is at `1p36.22`).
   - Line 59 states: *"Continuous data conforming to a normal distribution were presented as mean ± standard deviation; continuous data conforming to a normal distribution [sic] were presented as M (P25, P75)."*
   - Line 204 states that the `TT` genotype frequency is `42.2%`, contradicting `Table 2` line 103 (`95/215 = 44.2%`).
   - Neither serum folate/vitamin $\text{B}_{12}$ supplementation status nor continuous homocysteine concentration (`Hcy` in $\mu\text{mol/L}$, despite line 44 stating `Hcy` was collected) is reported in `Table 1`.

### 3. Biological / Experimental Grounding & Claim Proportionality
- **Claim 1:** Among hypertensive ischemic stroke patients, the *MTHFR* `677C>T` `T` allele and `TT` genotype are enriched in patients with homocysteine $\ge 10\ \mu\text{mol/L}$ (`H-type hypertension`, unadjusted `TT` `47.4%` vs. `17.4%`, $\chi^2 = 7.664, P = 0.022$). `[Well Supported]` — Replicates the well-known biochemical effect of *MTHFR* `C677T` (p.Ala222Val) on plasma homocysteine.
- **Claim 2:** In multivariate logistic regression adjusting for 14 clinical and lipid variables, the `TT` genotype has an independent $\text{OR} = 2.615$ ($P = 0.021$). `[Methodologically Flawed]` — The model is severely overfitted ($\text{EPV} = 1.53$ with 23 non-events and 15 predictors) and $\text{OR} = 2.615$ is the per-allele additive slope (`0, 1, 2`), not the `TT` genotype odds ratio.
- **Claim 3:** Combined *MTHFR* `677C>T` / `1298A>C` predicted enzyme activity categories (`NEA`, `MIMI`, `MOMI`, `EVMI` in `Table 7`) do not differ significantly between groups ($P = 0.229$), even though `677C>T` alone does. `[Fragile]` — Driven by collapsing `CT/AC` (higher in controls: `21.7%` vs `14.1%`) together with `TT/AA` (higher in cases: `46.4%` vs `17.4%`) into the same `EVMI` bucket in a 4-df test with only $n=23$ controls.

### 4. Reproducibility & Data Completeness
- **Strengths:** Ethics approval number (`[YEAR]-06-50`), genotype/haplotype counts (`Tables 2, 4, 5, 7`), and software versions (`SHEsis`, `SPSS 25.0`) are reported.
- **Deficiencies:** Swapped `TC`/`TG` rows in `Table 1`, missing continuous `Hcy` levels in `Table 1`, and arithmetic/coding inconsistencies across `Tables 1, 3, 4`.
</Blinded Review: TIME_ANON_0654>
